Metformin Aurobindo (Metformin Hydrochloride)

Metformin activates AMP‑activated protein kinase (AMPK), which suppresses liver glucose output, decreases intestinal glucose absorption, and enhances peripheral uptake of glucose into muscle and fat cells, thereby improving overall glycaemic control.

The appropriate dose of Metformin Aurobindo is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually.

Metformin’s safety in pregnancy is not fully established; it is generally avoided unless the potential benefit outweighs the risk. Limited data suggest it may be excreted in breast milk, so breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Metformin is often preferred as first‑line therapy for type 2 diabetes because it does not cause weight gain and has a low risk of hypoglycaemia compared with sulfonylureas or insulin. Its mechanism differs from newer agents such as SGLT2 inhibitors or GLP‑1 receptor agonists, which target renal glucose reabsorption or incretin pathways.

Metformin Aurobindo tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children.

Metformin Aurobindo is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets are swallowed whole with a glass of water; they should not be crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, excessive alcohol intake, or during acute illness. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in those receiving iodinated contrast media unless renal function is re‑evaluated after the procedure.